DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01890993

Completed

Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

4

Recruiting sites

—

Enrollment

952

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01890993
Org study IDNN2211-4077
Secondary IDENCEPP/SDPP/8135EU PAS
Secondary IDU1111-1142-2764WHO

Timeline

Milestones

Study first posted2013-07-02estimated
Last update posted2015-05-21estimated
Study start2013-08 (month precision)
Primary completion2014-06actual (month precision)
Study completion2014-06actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Consecutive patients with type 2 diabetes initiated on liraglutide or a DPP-4 inhibitor and primarily managed in primary care with 12 (+/-2) months of available data will be included in this study. Only data derived from patients receiving either therapy in accordance with license indications will be included and analyzed.

Inclusion criteria

•Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months

Exclusion criteria

•Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Glycemic / diabetes
1
Cardiometabolic biomarkers
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change in body weight

Time frame:Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Change in HbA1c (glycosylated haemoglobin)

Time frame:Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Change in systolic blood pressure

Time frame:Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.